Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-23339 in healthy subjects
NCT05093270Phase 1Completed
- Sponsor
- BeiGene
- Start
- Nov 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of bgb-23339 (4 arms), sponsored by BeiGene. Primary endpoints: Adverse Events at 7 weeks, Vital Signs at 4 weeks and 1 more. Started Nov 2021; status: completed.
02
Drugs
bgb-23339
Beyond the preview
Go deeper on NCT05093270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05093270.